Tigulixostat Alleviates Hyperuricemic Nephropathy by Promoting M2 Macrophage Polarization

Area of Science:

• Nephrology
• Pharmacology
• Immunology

Background:

• Serum uric acid (SUA) regulation involves hepatic purine metabolism and renal excretion.
• Kidney function is crucial for SUA homeostasis; impaired excretion contributes to hyperuricemia and kidney disease.
• Current treatments like URAT1 inhibitors carry risks, while xanthine oxidase (XO) inhibitors are standard but have limitations.

Purpose of the Study:

• To investigate the efficacy of Tigulixostat in reducing SUA levels and ameliorating hyperuricemic nephropathy (HN).
• To compare Tigulixostat's effects against allopurinol in a Uox-KO mouse model.
• To elucidate the mechanistic pathways underlying Tigulixostat's therapeutic action.

Main Methods:

• Utilized single-cell RNA sequencing, spatial metabolomics, plasma metabolomics, and flow cytometry.
• Employed a urate oxidase knockout (Uox-KO) mouse model to study hyperuricemia and kidney outcomes.
• Administered Tigulixostat and allopurinol for comparative analysis.

Main Results:

• Tigulixostat demonstrated superior reduction in SUA levels compared to allopurinol.
• Tigulixostat treatment led to improved renal outcomes in the Uox-KO mice.
• The drug effectively improved hyperuricemic nephropathy by promoting M2 macrophage polarization, without inducing liver injury.

Conclusions:

• Tigulixostat is a potent therapeutic agent for lowering SUA and treating hyperuricemic nephropathy.
• Its mechanism involves modulating macrophage polarization, offering a novel approach to kidney protection.
• Tigulixostat presents a promising alternative for managing hyperuricemia and related renal conditions.